Used in research as a potent inhibitor of mitochondrial complex I, IACS-010759 targets cancer cell metabolism, particularly in tumors reliant on oxidative phosphorylation. It shows promise in preclinical studies against certain brain cancers, leukemias, and other solid tumors with metabolic vulnerabilities. The compound helps investigate metabolic adaptation in cancer and supports development of therapies targeting energy pathways in malignant cells.